<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04899778</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00000922</org_study_id>
    <nct_id>NCT04899778</nct_id>
  </id_info>
  <brief_title>Do Oral Contraceptives Protect Against ACL Injuries in Female Athletes</brief_title>
  <acronym>OC</acronym>
  <official_title>Do Oral Contraceptives Protect Against Anterior Cruciate Ligament Injuries in Female Athletes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to examine the impact of one type of commonly used&#xD;
      birth control pill on blood levels of relaxin and measure changes in knee movement to&#xD;
      determine whether there are changes in joint instability (indicating the knee is less stable)&#xD;
      that may predispose female athletes to injury. Women not on hormonal birth control will also&#xD;
      be enrolled to analyze differences between athletes on and not on birth control and to&#xD;
      evaluate typical relaxin levels and knee laxity when birth control pills are not used.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ligamentous injury</measure>
    <time_frame>over the course of 1 year</time_frame>
    <description>ligament rupture or tear occurrence per athlete enrolled</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum relaxin level</measure>
    <time_frame>baseline, 4 month visit</time_frame>
    <description>level of relaxin measured in each subject</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anterior Knee Laxity</measure>
    <time_frame>baseline, 4 month visit</time_frame>
    <description>Anterior Knee laxity will be evaluated using the KT-2000 and measured in millimeters of anterior translation of the tibia relative to the femur</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hip rotation during a single-legged drop</measure>
    <time_frame>baseline, 4 month visit</time_frame>
    <description>Hip flexion, adduction, and internal/external and coronal plane rotation of the knee measured during a singled-legged drop using motion tracking equipment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knee rotation during a single-legged drop</measure>
    <time_frame>baseline, 4 month visit</time_frame>
    <description>Hip flexion, adduction, and internal/external and coronal plane rotation of the knee measured during a singled-legged drop using motion tracking equipment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Joint Hypermobility</measure>
    <time_frame>baseline, 4 month visit</time_frame>
    <description>Beighton score will be used to assess overall joint laxity. The Beighton score is on a nine-point scale that is based on 5 joint maneuvers. The maximum score is 9, which indicates hyperlax. A score of zero indicates tight joints.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Ligament Injury</condition>
  <arm_group>
    <arm_group_label>Oral Contraceptive Pill</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral contraceptive, 1/day, for one year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Oral Contraceptive</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Contraceptive Pill</intervention_name>
    <description>tablet</description>
    <arm_group_label>Oral Contraceptive Pill</arm_group_label>
    <other_name>Birth Control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  Currently playing basketball, soccer, or volleyball at Loyola Marymount or Pepperdine&#xD;
&#xD;
          -  If not currently on COC, regular menstrual cycle occurring every 21-35 days&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous ACL injury&#xD;
&#xD;
          -  Underlying neuromuscular disease&#xD;
&#xD;
          -  Medical contraindication to COC use&#xD;
&#xD;
          -  History of pregnancy&#xD;
&#xD;
          -  Desire to conceive in the next year&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 17, 2021</study_first_submitted>
  <study_first_submitted_qc>May 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2021</study_first_posted>
  <last_update_submitted>June 10, 2021</last_update_submitted>
  <last_update_submitted_qc>June 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Natasha Trentacosta</investigator_full_name>
    <investigator_title>Surgeon</investigator_title>
  </responsible_party>
  <keyword>anterior cruciate ligament</keyword>
  <keyword>birth control</keyword>
  <keyword>oral contraceptive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Contraceptives, Oral, Combined</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

